Igor Puzanov - Concepedia

Author

Igor Puzanov

Vanderbilt University Medical Center ORCID

Also Known As

I J Puzanov, I Puzanov, I. J. Puzanov, I. Puzanov, I.J. Puzanov, Igor J Puzanov, Igor J. Puzanov, Igor Puzanov, Kiera Rycaj, Puzanov, Igor

666

Publications

55.1K

Citations

H-Index

122

Concepts

All Affiliations

Vanderbilt University Medical Center Roswell Park Comprehensive Cancer Center Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

Igor Puzanov is an author at Vanderbilt University Medical Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	115	20.9K
2	Health Sciences	22	33	7.1K
3	Engineering	3	3	549
4	Public Health	1	1	22
5	Allergy	1	1	22

Igor Puzanov

221

Publications

49.5K

Citations

H-Index

Page 1

	Year	Citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Journal of Clinical Oncology ImmunohematologyCancer ImmunosurveillanceAutoimmune DiseaseMedicineImmunology	2018	3.6K
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, New England Journal of Medicine	2010	3.5K
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Journal of Clinical Oncology	2015	2.5K
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Suzanne L. Topalian, Mario Sznol, David F. McDermott, Journal of Clinical Oncology	2014	2.2K
Fulminant Myocarditis with Combination Immune Checkpoint Blockade Douglas B. Johnson, Justin M. Balko, Margaret Compton, New England Journal of Medicine Fatal MyocarditisCancer ImmunosurveillanceSkeletal MuscleMedicineFulminant Myocarditis	2016	2.2K
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, New England Journal of Medicine	2012	2.1K
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Gideon Bollag, Peter Hirth, James Tsai, Nature Skin CancerMedicineMelanomaClinical EfficacyPharmacology	2010	1.8K
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations David M. Hyman, Igor Puzanov, Vivek Subbiah, New England Journal of Medicine	2015	1.7K
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas, Igor Puzanov, Reinhard Dummer, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsImmune Checkpoint Inhibitor	2015	1.5K

Page 1